GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biocytogen Pharmaceuticals (Beijing) Co Ltd (HKSE:02315) » Definitions » Total Assets

Biocytogen Pharmaceuticals (Beijing) Co (HKSE:02315) Total Assets : HK$2,618.4 Mil (As of Jun. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Biocytogen Pharmaceuticals (Beijing) Co Total Assets?

Biocytogen Pharmaceuticals (Beijing) Co's Total Assets for the quarter that ended in Jun. 2024 was HK$2,618.4 Mil.

During the past 12 months, Biocytogen Pharmaceuticals (Beijing) Co's average Total Assets Growth Rate was -7.60% per year. During the past 3 years, the average Total Assets Growth Rate was 9.60% per year.

During the past 4 years, Biocytogen Pharmaceuticals (Beijing) Co's highest 3-Year average Total Assets Growth Rate was 9.60%. The lowest was 9.60%. And the median was 9.60%.

Total Assets is connected with ROA %. Biocytogen Pharmaceuticals (Beijing) Co's annualized ROA % for the quarter that ended in Jun. 2024 was -4.12%. Total Assets is also linked to Revenue through Asset Turnover. Biocytogen Pharmaceuticals (Beijing) Co's Asset Turnover for the quarter that ended in Jun. 2024 was 0.17.

Biocytogen Pharmaceuticals (Beijing) Co Total Assets Historical Data

The historical data trend for Biocytogen Pharmaceuticals (Beijing) Co's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biocytogen Pharmaceuticals (Beijing) Co Total Assets Chart

Biocytogen Pharmaceuticals (Beijing) Co Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Total Assets
2,757.93 2,819.68 3,126.61 2,679.11

Biocytogen Pharmaceuticals (Beijing) Co Semi-Annual Data
Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Total Assets Get a 7-Day Free Trial 2,548.96 3,126.61 2,972.66 2,679.11 2,618.39

Biocytogen Pharmaceuticals (Beijing) Co Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Biocytogen Pharmaceuticals (Beijing) Co's Total Assets for the fiscal year that ended in Dec. 2023 is calculated as

Total Assets=Total Equity (A: Dec. 2023 )+Total Liabilities (A: Dec. 2023 )
=864.562+1814.549
=2,679.1

Biocytogen Pharmaceuticals (Beijing) Co's Total Assets for the quarter that ended in Jun. 2024 is calculated as

Total Assets=Total Equity (Q: Jun. 2024 )+Total Liabilities (Q: Jun. 2024 )
=801.209+1817.184
=2,618.4

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biocytogen Pharmaceuticals (Beijing) Co  (HKSE:02315) Total Assets Explanation

Total Assets is connected with ROA %.

Biocytogen Pharmaceuticals (Beijing) Co's annualized ROA % for the quarter that ended in Jun. 2024 is

ROA %=Net Income (Q: Jun. 2024 )/( (Total Assets (Q: Dec. 2023 )+Total Assets (Q: Jun. 2024 ))/ count )
=-109.104/( (2679.111+2618.393)/ 2 )
=-109.104/2648.752
=-4.12 %

Note: The Net Income data used here is two times the semi-annual (Jun. 2024) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Biocytogen Pharmaceuticals (Beijing) Co's Asset Turnover for the quarter that ended in Jun. 2024 is

Asset Turnover
=Revenue (Q: Jun. 2024 )/( (Total Assets (Q: Dec. 2023 )+Total Assets (Q: Jun. 2024 ))/ count )
=441.92/( (2679.111+2618.393)/ 2 )
=441.92/2648.752
=0.17

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Biocytogen Pharmaceuticals (Beijing) Co Total Assets Related Terms

Thank you for viewing the detailed overview of Biocytogen Pharmaceuticals (Beijing) Co's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Biocytogen Pharmaceuticals (Beijing) Co Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biocytogen Pharmaceuticals (Beijing) Co Ltd (HKSE:02315) » Definitions » Total Assets
Comparable Companies
HKSE:01477 HKSE:02256 HKSE:01873 HKSE:02616 HKSE:02480 HKSE:02142 HKSE:02179 HKSE:01521 HKSE:09966 HKSE:06955 VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX XBRU:UCB ALNY ONC BNTX XKRX:068270
Traded in Other Exchanges
I54:Germany
Address
12 Baoshen South Street, Daxing Bio-Medicine Industry Park, Daxing District, Beijing, CHN
Website
https://www.biocytogen.com.cn
Biocytogen Pharmaceuticals (Beijing) Co Ltd is a biopharmaceutical and pre-clinical research services company. It has two Core Products, YH003 and YH001. YH003 is a recombinant humanized agonistic anti-Cluster of Differentiation 40 (CD40) Immunoglobulin G2 (IgG2) monoclonal antibody and YH001 is a recombinant humanized anti-CTLA-4, a protein receptor expressed constitutively on T cells that functions as an immune checkpoint and downregulates immune responses, Immunoglobulin G1 (IgG1) monoclonal antibody. YH003 is being developed for pancreatic ductal adenocarcinoma, melanoma, and other advanced solid tumors. YH001 is being developed for hepatocellular carcinoma (HCC), non-small-cell lung carcinoma (NSCLC), and other solid tumors.
Executives
Wei Ke Xiang Gang Jing Mao You Xian Gong Si 2101 Beneficial owner
Bvcf Realization Fund, L.p. 2201 Interest of corporation controlled by you
Zhao Yin Guo Ji Jin Rong You Xian Gong Si 2201 Interest of corporation controlled by you
Zhao Yin Guo Ji Jin Rong Kong Gu You Xian Gong Si 2201 Interest of corporation controlled by you
Prowell Ventures Pte Ltd 2201 Interest of corporation controlled by you
Gic Special Investments Private Limited 2102 Investment manager
Gic Private Limited 2201 Interest of corporation controlled by you
Gic (ventures) Pte. Ltd. 2201 Interest of corporation controlled by you
Yang Zhi 2201 Interest of corporation controlled by you
Innoveda Medtech, Ltd. 2201 Interest of corporation controlled by you
Ni Jian
Bvcf Realization Fund Gp, Ltd. 2201 Interest of corporation controlled by you
Bioveda China Fund Ii Rmb, Limited 2101 Beneficial owner
Cmbi Private Equity Series Spc 2201 Interest of corporation controlled by you
Cmb International Private Investment Limited 2201 Interest of corporation controlled by you

Biocytogen Pharmaceuticals (Beijing) Co Headlines

No Headlines